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Myosin binding protein C (MyBP-C) consists of a family of thick ﬁlament associated proteins. Three isoforms of MyBP-C exist
in striated muscles: cardiac, slow skeletal, and fast skeletal. To date, most studies have focused on the cardiac form, due to its
direct involvement in the development of hypertrophic cardiomyopathy. Here we focus on the slow skeletal form, discuss past
and current literature, and present evidence to support that: (i) MyBP-C slow comprises a subfamily of four proteins, resulting
from complex alternative shuﬄing of the single MyBP-C slow gene, (ii) the four MyBP-C slow isoforms are expressed in variable
amounts in diﬀerent skeletal muscles, (iii) at least one MyBP-C slow isoform is preferentially found at the periphery of M-bands
and (iv) the MyBP-C slow subfamily may play important roles in the assembly and stabilization of sarcomeric M-a n dA-bands
and regulate the contractile properties of the actomyosin ﬁlaments.
1.Introduction
Myoﬁbrils, the workhorses of skeletal muscle, consist of
interdigitating thick and thin ﬁlaments, and their associated
membrane systems [1]. Muscle contraction and relaxation is
mediated by the sliding of thick myosin ﬁlaments past thin
actin ﬁlaments, under the strict regulation of Ca2+ release
and reuptake via the sarcoplasmic reticulum (SR) [2]. In
addition to housing the basic thick and thin ﬁlaments, the
sarcomere also contains several accessory proteins that are
involved in the assembly, maintenance, and regulation of
contractile activity [1]. Myosin Binding Protein-C (MyBP-
C) comprises a family of accessory proteins that contributes
to the assembly and stabilization of thick ﬁlaments, and
regulates the formation of cross-bridges between myosin and
actin by interacting directly with both ﬁlamentous systems
(as reviewed in [3]).
MyBP-C was originally identiﬁed from mammalian
skeletalmuscleasanimpurityofisolatedmyosin.UsingSDS-
polyacrylamide gel electrophoresis (SDS-PAGE), Star and
Oﬀer were the ﬁrst to separate a number of unidentiﬁed
myosin-associated proteins that were consistently found in
preparations of puriﬁed myosin [4]. MyBP-C, originally
termed C-protein for its location on SDS-PAGE as band
C, was further characterized as a myosin binding protein
of ∼140kDa using a combination of biochemical methods,
ranging from gel ﬁltration, to ammonium sulfate fraction-
ation and single molecule electron microscopy [4–6]. The
location of MyBP-C at striped intervals within the C-zone
of the A-band of skeletal muscle was ﬁrst observed with X-
ray diﬀraction and immunoelectron microscopy [7], further
supporting its association with the thick myosin ﬁlaments.
Subsequent studies revealed that MyBP-C is arranged along
the length of the A-band in 7–9 transverse stripes that are
∼43nm apart, with ∼2–4 molecules of MyBP-C associating
with each myosin cross-bridge [8–11].
The family of MyBP-C contains three isoforms: cardiac,
slow skeletal, and fast skeletal, which are encoded by separate
genes; in humans, these map to chromosomes 11, 12,
and 19, respectively [12, 13]. The diﬀerent isoforms have
been cloned and sequenced from various species, including
human, chicken, rabbit and mouse, allowing a thorough
comparison of their molecular composition and primary
sequence [13–16]. An ∼65% identity is shared among the
individualisoformsacrossspecies,whilean ∼50%homology
is shared among the human cardiac, slow and fast forms.2 Journal of Biomedicine and Biotechnology
The core structure of MyBP-C is composed of seven
immunoglobulin (Ig) domains and three ﬁbronectin type
III (Fn-III) repeats, numbered from the NH2-terminus as
C1–C10 [17]. The C1 domain is ﬂanked by two unique
motifs, one enriched in proline and alanine residues, termed
proline/alanine rich motif and a conserved linker, referred
to as MyBP-C motif. Notably, the cardiac isoform possesses
three additional features, which are absent from the skeletal
forms of the protein. These include an Ig domain at
the extreme NH2-terminus of the molecule, termed C0, a
unique 9-residues long insertion within the MyBP-C motif
containing phosphorylation sites necessary for the protein’s
regulatory role in contraction, and a 28-amino acids long
loop in the middle of the C5 domain [12, 16].
In mammals, cardiac MyBP-C is expressed early in
development, along with titin and myosin [18, 19]. The
skeletal isoforms of MyBP-C, however, are detected later
in development, after the expression of titin and myosin,
with the expression of slow MyBP-C preceding that of fast
[18, 20]. By contrast, in chicken skeletal muscles the slow
and fast isoforms appear concurrently at the end of late
embryogenesis [21]. As development proceeds, though, the
amounts of the slow form diminish, while the expression
of the fast form persists through adulthood [21]. The fast
and slow skeletal isoforms have been shown to coexpress
in the same muscle type and can even coexist in the same
sarcomere; expression of the cardiac isoform, however, is
restrictedtothedevelopingandmatureheart[15,18,22–24].
Interestingly,arecentstudydemonstratedthattheexpression
of MyBP-C slow is not restricted to skeletal muscle but is also
evidenced in the right atrium and interatrial septum of adult
mammalian cardiac muscle [25].
To date, much of our knowledge on the molecular
properties and functional activities of MyBP-C originates
fromthenumerousstudiesthatfocusonthecardiacisoform.
The reader is referred to excellent reviews discussing the
structure of cardiac MyBP-C, its key roles in maintaining
the normal structure of thick ﬁlaments and regulating cross-
bridge cycling, and its involvement in the development of
hypertrophic cardiomyopathy [3, 26, 27] .H e r e ,w ewi l lf o c u s
ontheslowform(s)ofMyBP-Cfoundinskeletalmuscles.We
will review past and current literature, discuss its role in the
organizationandstabilizationofthickﬁlaments,andprovide
evidence that MyBP-C slow comprises a subfamily of four
alternatively spliced proteins that are expressed in variable
amounts in slow and fast twitch skeletal muscles.
2.MaterialsandMethods
2.1. Reverse Transcription-Polymerase Chain Reaction. Total
RNA was isolated with Trizol reagent (Invitrogen, Carls-
bad, CA) from P1 rat skeletal myotubes cultured for
seven days and from adult rat extensor digitorum longus
(EDL), ﬂexor digitorum brevis (FDB), tibialis anterior (TA),
gastrocnemius (gastroc), quadriceps (quad), and soleus
muscles. Aliquots containing ∼5μg of RNA were reverse
transcribed using the Superscript First Strand Synthesis
System for RT-PCR (Invitrogen, Carlsbad, CA) following the
manufacturer’s instructions. PCR ampliﬁcation of MyBP-
C slow transcripts was performed with primer sets that
ﬂanked each of the three insertions; for the NH2-terminal
insert: Forward-1 (F1): 5  CCAGAACCCACTAAGAAAG 3 
and Reverse-1 (R1): 5  GATCCTCGAGGTGCACTT CAA-
GATCAA 3 , for the insert within Ig7: Forward-2 (F2):
5  GATCGAATTCAGCCC TCCTACTCTT 3  and Reverse-
2 (R2): 5  GATCCTCGAGGGGCTCGCTGGCACCA 3  and
for the COOH-terminal insert: Forward-3 (F3): 5  CACC-
CATGTTTACTCAACCCT 3  and Reverse-3 (R-3) 5  GTGA-
CAATATACATTGAA 3 . To amplify the COOH-terminal
insert from EDL and TA muscles, it was necessary to
reamplify 0.5μL of the original PCR for an additional 30
cycles for a total of 80 cycles. All other PCRs were carried out
for 50 cycles. PCR products were analyzed by electrophoresis
in 1% agarose gels and their authenticity was veriﬁed by
sequence analysis.
2.2. Generation of Protein Lysates from P1 Myotubes and Adult
RatMuscle. HomogenatesofP1myotubesculturedforseven
days as well as of EDL, FDB, TA, gastrocnemious, quadriceps
and soleus muscles of adult Sprague-Dawley rats (Zivic-
Miller Laboratories, Zelienople, PA) were prepared at RT
with a Brinkman Polytron homogenizer at setting 3 (VWR,
West Chester, PA) in 10mM NaPO4,p H7 . 2 ,2m ME D T A ,
10mM NaN3, 120mM NaCl, 0.5% deoxycholate, 0.5% NP-
40, supplemented withComplete protease inhibitors (Roche,
Indianapolis, IN). Each sample (∼60μg) was solubilized in
4xNuPAGE reducing sample buﬀer (Invitrogen, Carlsbad,
CA) at 90
◦C for 5 minutes, fractionated by 4–12% SDS-
PAGE BisTris gel using MES running buﬀer (Invitrogen,
Carlsbad, CA), transferred to nitrocellulose and probed with
an antibody that recognizes the slow forms of MyBP-C
(300ng/mL, Abnova) or with an antibody that speciﬁcally
recognizes the COOH-terminal insert [28]. After incubation
with the appropriate secondary antibodies, immunoreactive
bands were visualized with a chemiluminescence detection
kit (Tropix, Bedford, MA).
2.3. Immuno-Electron Microscopy. Immuno-electron mi-
croscopy was performed as previously described with minor
modiﬁcations [29, 30]. Brieﬂy, adult mouse FDB skeletal
muscle was ﬁxed both in situ, via whole animal perfusion-
ﬁxation and ex vivo with 2% paraformaldehyde in PBS.
Samples were snap-frozen in a slush of liquid N2,c r y o s e c -
tioned (∼20μm thick), and incubated overnight at 4◦C
with the antibody that speciﬁcally recognizes the COOH-
terminal insert of MyBP-C slow. Samples were incubated
with secondary goat antirabbit IgG adsorbed on 1nm
gold particles (Nanoprobes Incorporated; Yaphank, NY)
and subsequently with ﬂuorescein-conjugated antigoat IgG
(Jackson ImmunoResearch Laboratories Inc., West Grove,
PA). Samples were enhanced with silver (HiQ Silver Kit,
Nanoprobes) for 5 minutes, ﬁxed overnight at 4◦Ci n
2% gluteraldehyde and 5mg/mL tannic acid in 0.2M
cacodylate buﬀer and postﬁxed with 50mM acetate buﬀer
1% osmium tetroxide. They were further stained en bloc
for 2 hours with 1% uranyl acetate in 65% ethanol,Journal of Biomedicine and Biotechnology 3
dehydrated, and embedded in araldite (Electron Microscopy
Sciences, Fort Washington, PA). Ultrathin (60–90nm) sec-
tions were prepared with an MT5000 ultramicrotome (LKB
instruments Inc., Gaithersburg, MD), mounted on grids,
labeled with 1% uranyl acetate followed by Reynolds lead
citrate, and examined with a Philips-201 electron micro-
scope.
3. Results andDiscussion
3.1. MyBP-C Slow: A Subfamily of Proteins. To date, four
diﬀerent MyBP-C slow transcripts have been identiﬁed in
h u m a ns k e l e t a lm u s c l er e f e r r e dt oa sv a r i a n t s1 – 4( Figure 1;
accession numbers NM 002465, NM 206819, NM 206820,
and NM 206821, respectively). The four variants diﬀer from
one another at three regions, due to alternative splicing
events that result in inclusion of exons 3 and 4 in the
proline/alanine-rich motif, exon 23 in the Ig7 domain and
exon 31 at the extreme COOH-terminus (Figure 1(a)); these
encode novel sequences of 25 (Figure 1(b)), 18 (Figure 1(c)),
and 26 (Figure 1(d)) amino acids, respectively. Analysis of
the primary sequence of the four MyBP-C slow variants
indicated that variants 1 and 2 contain the NH2-terminal
insertion located in the proline/alanine rich motif, variant 3
carries the insertion within domain Ig7, while variant 1 also
contains the unique COOH-terminal region (Figure 1(a)).
Notably, variant 3 is the prototypical human isoform of
MyBP-C slow that was characterized by Furst and colleagues
in 1992 [14].
To study the relative expression of the four MyBP-C
slow transcripts in diﬀerent rat skeletal muscles, we used
RT-PCR analysis to amplify the unique regions described
above. To this end, we prepared cDNAs from a panel of adult
and developing rat skeletal muscles that contained distinct
compositions of slow and fast twitch skeletal myoﬁbers.
These included extensor digitorum longus (EDL; ∼90:10,
fast:slow; [31, 32]), ﬂexor digitorum brevis (FDB; ∼80:20,
fast:slow; [33]), tibialis anterior (TA; ∼70:30, fast:slow;
[34]), gastrocnemius (gastroc; ∼40:60, fast:slow; [35]),
quadriceps (quad; ∼60:40, fast:slow; [36]), soleus (20:80,
fast:slow,[35]),andhindlimbskeletalmyotubesofpostnatal
day 1 (P1) rat pups (Figure 2). Primer sets were designed
to ﬂank each of the three novel insertions (Figures 2(a)–
2(c), cartoons in the upper left corner). Ampliﬁcation of
two PCR products with distinct sizes within each reaction
indicated the presence of a mixed population of transcripts
that contained (larger size product) and lacked (smaller
size product) the respective insertion. On the contrary,
ampliﬁcation of one PCR product indicated the presence
of a homogeneous population of transcripts that either
includedorexcludedthecorrespondinginsertion,depending
on its size. Accordingly, PCR products that carry the NH2-
terminal, Ig7 and COOH-terminal inserts would be ∼600,
∼310, and ∼350 nucleotides long, respectively, whereas PCR
products that lack them would be ∼530, ∼260, and ∼290
nucleotides long, respectively.
All skeletal muscles examined, independent of their ﬁber
type composition, contained suﬃcient amounts of MyBP-C
slow transcripts to be ampliﬁed by conventional RT-PCR.
Figure 2(a) shows the results following ampliﬁcation of the
NH2-terminal insertion located within the proline/alanine
r i c hm o t i f .A l lm u s c l es a m p l e se x p r e s sM y B P - Cs l o wt r a n -
scriptsthatincludetheNH2-terminalinsert,albeittovarying
degrees, as seen by the presence of an ∼600nts amplicon
(Figure 2(a), upper band). This ﬁnding suggested that all
muscles tested express variants 1 and/or 2, with EDL, TA,
andsoleuscontainingthehighestamounts.Notably,allseven
muscles also contain diﬀerent amounts of transcripts that
lack the NH2-terminal insert, as shown by the presence
of an ∼530nts product, indicating that they also express
variants 3 and/or 4, with FDB showing the highest levels
(Figure 2(a), lower band). Contrary to EDL, TA, soleus,
and FDB that appear to preferentially contain MyBP-C
slow variants that either include (EDL, TA and soleus) or
exclude (FDB) the NH2-terminal insert, gastroc, quad, and
P1 myotubes show similar amounts of both ampliﬁcation
products, suggesting that transcripts possessing and lacking
the NH2-terminal insert may exist in similar levels within
these muscles (Figure 2(a) lanes 4-5 and 7).
Next, we extended our analysis to the second novel
insertion located within Ig7. As before, our primers set was
designed to amplify MyBP-C slow variants that contained or
skipped the Ig7 insert. Only soleus and P1 myotubes possess
transcripts that include the unique insertion within Ig7, as
indicated by the presence of an ∼310nts band (Figure 2(b),
lanes 6 and 7, upper band), corresponding to variant 3. As
expected, all skeletal muscles tested contained transcripts
that lack the Ig7 insertion, as shown by the ampliﬁcation
of an ∼260nts product, representing variants 1, 2 and/or 4.
Thus, variant 3 is restricted to soleus muscle and developing
myotubes.
Last, we generated the appropriate primers to amplify
the region ﬂanking the COOH-terminal insert of MyBP-
C slow. With the exception of quadriceps muscle, all other
muscles tested, contained an ampliﬁcation product of ∼350
nucleotides, that includes the novel COOH-terminal insert
detected only in variant 1, with soleus and FDB showing the
highest amounts (Figure 2(c), lanes 6 and 2, upper band).
As e c o n da m p l i ﬁ c a t i o np r o d u c to f∼290 nucleotides was
also detected in all seven muscles, which lacks the unique
COOH-terminal insertion, present in variant 1, but includes
the common COOH-terminal region shared by variants 2, 3,
and 4 (Figure 2(c), lower band).
The RT-PCR data is summarized in Table 1.T a k e n
together, our results suggest that: (i) mRNA encoding MyBP-
C slow is present in all skeletal muscles examined, regardless
of ﬁber type composition or age, and (ii) complex alternative
shuﬄing of the single MyBP-C slow gene in the various
muscles results in the diﬀerential expression of the four
MyBP-C slow isoforms.
To correlate the mRNA expression of the transcripts
that contain or lack the three novel insertions, as seen
by the RT-PCR, to the expression of the proteins that
they encode, we used western blot analysis. Homogenates
from EDL, FDB, TA, gastroc, quad, soleus, and P1 skeletal
myotubes were separated on 4–12% gradient gel, which
our laboratory has previously shown to provide optimal4 Journal of Biomedicine and Biotechnology
C1 C2 C3 C4 C5 C6 C7 C8 C9 C10
C1 C2 C3 C4 C5 C6 C7 C8 C9 C10
C1 C2 C3 C4 C5 C6 C7 C8 C9 C10
C1 C2 C3 C4 C5 C6 C7 C8 C9 C10
Variant 1 : 131.7kDa
Variant 2 : 129.1kDa
Variant 3 : 128.3kDa
Variant 4 : 126.5kDa
(a)
-EEEVSPPSALPPGLGSRALERKDSD-
-GATGAAGAGGAAGTCTCCCCGCCTAGCGCCTTGCCTCCAGGTTTGGGTAGTCGGGCCCTGGAGAGAAAAGATTCA-
NH2-terminal insert
C1
Exon 3 Exon 4
(b)
-STSAKQSDENGEAAYDLPA-
-AGTACATCAGCAAAACAGTCTGATGAAAATGGGGAGGCTGCCTATGATCTGCCAGCT-
Ig7 insert
C7
Exon 23
(c)
-IYQGVNTPGQPVFLEGQQQSLHNKDF-
-GATATATCAAGGAGTAAATACCCCTGGACAACCAGTCTTCCTGGAGGGGCAGCAACAGTCATTGCACAATAAGGATTTT-
COOH-terminal insert
C10
Exon 31 Exon 32
(d)
Figure 1: (a): Schematic representation of MyBP-C slow variants 1–4, showing their common structural motifs and novel insertions; white
and grey ovals represent Ig and FN-III domains, respectively, while green, yellow, and red rectangles correspond to the NH2-terminal, Ig7,
and COOH-terminal inserts, respectively. The NH2-terminal insert is present in variants 1 and 2, while the Ig7 and COOH-terminal inserts
are present in variants 3 and 1, respectively. Variant 4 does not contain any of the three inserts. (b–d): Complex alternative splicing events
result in the inclusion of exons 3 and 4, exon 23 and exon 31 that encode the NH2-terminal (b), Ig7 (c), and COOH-terminal (d) novel
insertions. The amino acid and nucleotide compositions of the three insertions are shown.
separation of the MyBP-C slow isoforms (see Section 2,
and [28]). Homogenates were probed with a commer-
cial antibody that recognizes a region within domain C5
common to all MyBP-C slow variants (Figure 3(a)). We
were able to resolve at least 3 immunoreactive bands
based on their distinct electrophoretic mobilities. The top
band may represent variant 1 (∼132kDa, Figure 3(a),t o p
panel, marked with a blue dot), the middle band may
correspond to variants 2 and/or 3 (∼129 and ∼128kDa,
respectively, Figure 3(a), top panel, denoted with a red dot),
and the bottom band may represent variant 4 (∼126kDa,
Figure 3(a), top panel, marked with a green dot). The
cartoon shown in the bottom panel of Figure 3(a) illustrates
a representative image of several western blots, analyzed at
varyingexposuretimes.Thedottedlinesindicateimmunore-
active bands that only become evident after periods of long
exposure.
Consistent with the RT-PCR data, our immunoblots
also demonstrated the presence of at least one form of
MyBP-C slow in each skeletal muscle tested. EDL and
gastrocnemious possess three immunoreactive bands with
the most prominent being the middle one (Figure 3(a),l a n e s
1 and 4). FDB also contains three distinct bands, however,
the top and middle bands appear to be of similar intensities
and occasionally appear as a broad, single band (Figure 3(a),
lane 2). Similar to FDB, TA also shows two closely migrating
bands, but lacks the bottom one (Figure 3(a) lane 3).
Contrary to the rest of the muscles analyzed, quadricepsJournal of Biomedicine and Biotechnology 5
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Figure 2: RT-PCR analysis using cDNA generated from developing
and adult rat extensor digitorum longus (EDL), ﬂexor digitorum
brevis (FDB), tibialis anterior (TA), gastrocnemius (gastroc),
quadriceps (quad) and soleus skeletal muscles and primer sets
designed to ﬂank the NH2-terminal (a), Ig7 (b), and COOH-
terminal (c) insertions. A schematic representation of the ampliﬁed
region is shown in the upper left corner of each panel. White
and grey ovals depict Ig and FN-III domains, respectively, while
the 3  UTR is shown as a black line. The zig-zag lines denote the
three novel insertions. In each ampliﬁcation reaction, the top band
corresponds to transcripts that include the insertion of interest,
whereasthebottombandcorrespondstotranscriptsthatlackit.(a):
All skeletal muscles tested contain a mixed population of MyBP-C
slow variants that contain and lack the NH2-terminal insertion, as
indicatedbythepresenceoftwoampliﬁcationproducts.(b):Onthe
contrary, only soleus and developing myotubes express transcripts
that include the Ig7 insertion. (c): With the exception of quadriceps
muscle that only contains MyBP-C slow variants that lack the
COOH-terminal insertion, all other muscles examined contain a
mixed pool of transcripts that carry and lack the novel COOH-
terminal insertion.
appears to contain only the middle band, although, the
bottom one becomes evident after long exposure times
(Figure 3(a) lane 5). Soleus expresses high amounts of the
upper and lower bands, but moderate to low amounts of
the middle one (Figure 3(a) lane 6). Finally, developing P1
skeletal myotubes show only one immunoreactive band with
the same mobility as the top one, however, following longer
exposure, the middle immunoreactive band is also apparent
(Figure 3(a) lane 7).
Table 1: Tabulated summary of the RT-PCR data shown in
Figure 2. The plus (+) and minus (−) signs denote the presence
or absence of mRNAs encoding the three regions of interest,
respectively; the relative abundance of the respective transcripts is
illustrated by the number of plus signs.
Muscle Type NH2-insert Ig7-insert COOH-insert
Extensor Digitorum Longus ++ − +
Flexor Digitorum Brevis + − ++
Tibialis Anterior + + + − +
Gastrocnemius ++ − +
Quadriceps ++ −−
Soleus ++++ + +++
P1 Myotubes +++ ++ +
We also probed the same muscle homogenates with
an antibody that is speciﬁc for the COOH-terminal insert
and therefore only recognizes MyBP-C slow variant 1
(Figure 3(b)). With the exception of quadriceps, all of the
other muscles were immunopositive for variant 1. This
ﬁnding is in agreement with our immunoblot data shown
in panel A, and the RT-PCR analysis shown in Figure 2(c),
which revealed that quadriceps was the sole muscle to
lack the top immunoreactive band (i.e., variant 1) and
the COOH-terminal insert, respectively. Notably, MyBP-C
slow variant 1 appears to be expressed more abundantly in
soleusmuscleandleastprominentlyindevelopingmyotubes,
while the remaining muscles tested contained intermediate
amounts. The slight diﬀerences in the sizes of the bands
detected in the diﬀerent muscles are likely due to posttrans-
lation modiﬁcations, as it has previously been shown that
MyBP-C slow is capable of phosphorylation [37, 38].
Taken together, our RT-PCR and immunoblotting data
(summarizedinTable 2)clearlyindicatethatallskeletalmus-
cles tested, apart from quadriceps, express variant 1, albeit to
diﬀerent extents, with soleus and FDB containing the highest
amounts. Variants 2 and 3 have complementary expression
proﬁles, with variant 2 being preferentially expressed in
muscles that have a higher composition of fast twitch ﬁbers,
such as EDL, FDB, TA, gastrocnemious and quadriceps, and
variant 3 being selectively present in slow twitch muscles,
like soleus, and developing myotubes. Finally, variant 4 is
detected in all muscles examined, with the exception of TA
and developing myotubes. It therefore appears that diﬀerent
forms of MyBP-C slow are present within the same muscle,
independently of its ﬁber type composition, developmental
stage, or age.
3.2. MyBP-C at the A-band. Early studies have conﬁrmed
the direct interaction between MyBP-C and myosin and
identiﬁed the sites of binding on both proteins. The light
meromyosin (LMM) region of the myosin rod, that forms
the backbone of the thick ﬁlament, binds the COOH-
terminal C10 region of all three MyBP-C isoforms [39–41].
Positively charged residues on the surface of the C10 domain
mediate binding to LMM [42], however, the interaction
is signiﬁcantly strengthened by the presence of the C86 Journal of Biomedicine and Biotechnology
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Figure 3: Western blot analysis of protein homogenates prepared
from rat skeletal muscles and blotted with antibodies to the ﬁfth Ig
domain that recognize all MyBP-C slow variants (a) or to the novel
COOH-terminal insertion that speciﬁcally recognizes variant 1 (b).
(a) Top panel: With the exception of quadriceps, all other muscles
express variant 1, represented by the upper most band, marked by
a blue dot. All adult skeletal muscles tested, but not the developing
myoﬁbers, express variants 2 and/or 3, corresponding to the band
with the intermediate mobility, and denoted with a red dot. As
variants 2 and 3 have similar molecular weights (129 and 128kDa,
respectively), it is not feasible to separate them in the current gel
system. Moreover, variant 4 is detected in homogenates prepared
from EDL, FDB, gastrocnemious, and soleus, and is represented by
the lower immunoreactive band, marked with a green dot. Bottom
panel: A cartoon showing the presence of the diﬀerent MyBP-C
slow variants in developing and adult skeletal muscles. Dotted lines
correspond to immunoreactive bands, which are evident only after
long exposure times. (b) In agreement with the immunoblot shown
inpanel(a),antibodiesspeciﬁcforthenovelCOOH-terminalinsert
demonstrated that EDL, FDB, TA, gastrocnemious, soleus, and P1
skeletal myotubes express variant 1, with soleus containing the
highest amounts.
and C9 regions. Another interaction between the MyBP-
C motif, located at the NH2-terminus of MyBP-C and
subfragment 2 (S2) of myosin has been also identiﬁed, albeit
ofweakeraﬃnity[43].Inadditiontobindingmyosin,MyBP-
Cassociateswithactin,inaCa2+ dependentmanner,through
its NH2-terminal proline/alanine rich motif [44–46]. The
ability of MyBP-C to directly interact with both myosin
and actin facilitates its role as a regulator of cross-bridge
formation during contraction. Interestingly, at low ionic
strength MyBP-C inhibits actomyosin ATPase activity, while
at higher ionic strength it acts as a mild activator [47, 48].
In addition to myosin, MyBP-C also associates with titin
at the A-band [14, 49–51]. The COOH-terminal C8-C10
Table 2: MyBP-C slow variants 1–4 are present in varying amounts
in diﬀerent skeletal muscles. A plus (+) sign indicates the presence
of the respective variant in a select muscle. The relative abundance
of variants 1–4 in the skeletal muscles tested is illustrated by the
number of plus signs.
Muscle Type Variant 1 Variant 2 Variant 3 Variant 4
Extensor Digitorum
Longus
++ +++ — ++
Flexor Digitorum
Brevis
+++ ++ — ++
Tibialis Anterior ++ ++ — —
Gastrocnemius ++—+
Quadriceps —+ +——
Soleus ++++ — + +++
P1 Myotubes ++ — + —
domains of MyBP-C directly bind to the 11-domain super-
repeat [Ig-(FN-III)2-Ig-(FN-III)3-Ig-(FN-III)3] present in
the C-zone portion of titin, and speciﬁcally the ﬁrst Ig
domain, although ﬂanking motifs further strengthen the
interaction [52, 53]. Notably, the arrangement of MyBP-
C in 11 transverse stripes at regular intervals of ∼43nm
corresponds to that of the 11-domain super-repeat of
titin, to which MyBP-C binds. Consequently, It has been
suggested that binding to titin’s super-repeats speciﬁes the
subsarcomeric distribution of MyBP-C in the C-zone of the
A-band [52].
Recent studies have proposed that MyBP-C forms a
trimeric “collar” around each thick ﬁlament in which
domains C5–C7 of one molecule overlap with domains C8–
C10 of the neighboring molecule [54, 55]. In vitro binding
studies using the respective peptides postulated that this
arrangement might apply to the cardiac and fast skeletal
isoforms, but not the slow isoform. Interestingly, for these
studies Flashman and coworkers generated a recombinant
protein that contained domains C8–C10, present in all
four slow variants, followed by the novel COOH-terminal
insertion, present only in variant 1. It is, therefore, possible
thatthepresenceoftheCOOH-terminal26-aminoacidsmay
inhibit binding of the C8–C10 domains of variant 1 to the
C5–C7 domains of the neighboring molecule of MyBP-slow.
Indeed, this is consistent with our recent studies indicating
that variant 1 is preferentially localized at the periphery of
the M-band [28]. Conversely, an interaction between the
respective motifs present in variants 2–4 is likely, as these
containashortCOOH-terminusfollowingdomainC10that,
similar to the cardiac and fast isoforms, consists of four
amino acids.
Through its interactions with myosin and titin, MyBP-
C contributes to the stabilization and maintenance of the
sarcomeric A-band. In vitro studies indicate that myosin
ﬁlaments are capable of forming in the absence of MyBP-
C, however, its addition results in increased ﬁlament length,
and improved structure and uniformity across the ﬁlament
[40, 56, 57]. Additionally, in vivo deletion of the myosinJournal of Biomedicine and Biotechnology 7
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Figure 4:Ultrathincryo-sectionsofadultmouseFDBskeletalmusclewerelabeledwithantibodiesspeciﬁcfortheCOOH-terminalinsertion
present in MyBP-C slow variant 1. (a) Variant 1 was detected at the periphery of the M-band (arrows). The boxed area in (a) is blown up in
(b) for ease of visualization of the immunolabeling. Scale bar corresponds to 0.5μm.
and titin binding sites on MyBP-C results in disorganized A-
bands [58, 59]. Consistent with this, the C8–C10 domains
that harbor the binding sites for myosin and titin are
deleted in patients suﬀering from familial hypertrophic
cardiomyopathy [3, 60, 61]. Interestingly, though, normal
A-bands are formed in animals deﬁcient of cardiac MyBP-
C[ 62, 63], suggesting the presence of a compensatory
mechanism that maintains the myosin and titin ﬁlaments
within the A-band of the sarcomere. Taken together, these
studies suggest that MyBP-C, through its direct interaction
with myosin and titin, and possibly its self-association, may
stabilize the sarcomeric A-band.
In addition to maintaining the structure of thick ﬁl-
aments, MyBP-C may also play key roles in regulating
contractile function by modulating the rate of cross-bridges
formation. Consistent with this, in cardiomyocytes lacking
MyBP-C, actomyosin ﬁlaments exhibited increased power
output during contraction and faster rates of force develop-
mentathalfmaximalCa2+ activation[64].Reintroductionof
the NH2-terminal region of cardiac MyBP-C, containing the
myosin S2 binding site (i.e., domains C1 and C2), enhanced
Ca2+ sensitivity and restored the contractile properties of the
n u l lc a r d i o c y t e st on o r m a ll e v e l s[ 65], suggesting that car-
diac MyBP-C contributes to the regulation of myoﬁlament
tension and their cycling rates.
Contrary to the cardiac isoform that has been directly
implicated in the regulation of the contractile properties
of cardiomyocytes (reviewed in [3]), studies focusing on
the function of the skeletal forms of MyBP-C are limited.
However, early studies have suggested that the role of MyBP-
Cinskeletalmusclelikelyparallelsthatofthecardiacisoform
[66].Consistentwiththis,theamountsofMyBP-Cslowwere
recently found signiﬁcantly increased in EDL muscles from a
mousemodelinwhichthekinasedomainoftitinwasdeleted
[67]. Deﬁcient EDL muscles exhibited reduced myoﬁlament
Ca2+ sensitivity and altered contractile properties, which
were restored to normal levels upon extraction of MyBP-C
slow. Contrary to the slow form of MyBP-C, the fast form
was signiﬁcantly downregulated in the same muscles, while
the expression levels of other proteins of the A-a n dM-
bands remained unaﬀected. It is, therefore, likely that the
kinasedomainoftitinaﬀectstheexpressionofgenesinvolved
in the regulation of myoﬁlament Ca2+ sensitivity and force
production. Experimental evidence has therefore started to
emerge suggesting a key role for the skeletal forms of MyBP-
C in modulating contractility, too.
3.3. Mybp-C Slow Variant 1 Selectively Concentrates at the M-
Band. The presence of MyBP-C slow at the C-zones of the
A-band has been studied extensively during the last three
decades [3, 26, 68]. Recent studies from our laboratory,
however, have provided evidence that at least one form of
MyBP-C slow, speciﬁcally variant 1, has a unique topogra-
phy in the muscle cell [28]. Detailed immunoﬂuorescence
studies combined with confocal microscopy demonstrated
that MyBP-C slow variant 1 is selectively localized at the
periphery of the M-band in adult rat soleus muscle [28].
The unique localization of MyBP-C slow variant 1 is further
supported by our ultrastructural studies, shown in Figure 4.
Immunolabeling of ultrathin cryosections prepared from
adult mouse FDB muscle with antibodies to the unique
COOH-terminus of variant 1 also demonstrated that it pref-
erentiallyconcentratesattheedgesofthesarcomericM-band
(Figures 4(a)–4(b), arrowheads). Thus, it appears that the
diﬀerent MyBP-C slow isoforms have distinct distributions
in skeletal myoﬁbers, with variants 2–4 localizing at the A-
band and variant 1 at the M-band.
At the M-band, MyBP-C slow variant 1 interacts with
obscurin and four and a half lim protein 1 (FHL1) [28, 69].
The second Ig domain of obscurin and the last Ig domain
of MyBP-C slow variant 1 are both necessary and suﬃcient
to support their interaction, however, binding is enhanced
signiﬁcantly in the presence of the novel 26 amino acids
at the COOH-terminus of variant 1. Overexpression of the
second Ig domain of obscurin in primary cultures of skeletal
myotubes inhibited the integration of MyBP-C slow variant
1 at the M-band and severely disrupted the formation of
M-a n dA-bands. These ﬁndings suggested that variant 1
might contribute to the assembly and integrity of these
structures via its interaction with obscurin and possibly
other proteins. Similarly, McGrath et al. also demonstrated8 Journal of Biomedicine and Biotechnology
that overexpression or downregulation of FHL1, which is
localized at the A-I junction and the M-band, in adult
m o u s es o l e u sm u s c l er e s u l t e di ni m p a i r e dt h i c kﬁ l a m e n t
assembly, which was accompanied by reduced sarcomeric
incorporation of diﬀerent forms of MyBP-C slow, including
variant 1 [69].
3.4. MyBP-C Slow in Muscle Disease. Mutations within the
cardiac isoform of MyBP-C cause familial hypertrophic
cardiomyopathy (reviewed in [70, 71]). To date, there are
no muscle diseases causally associated with mutations in
the transcripts of the skeletal forms of MyBP-C. However,
changes in the expression levels of the skeletal isoforms
have been reported in hypertrophic and dystrophic skele-
tal muscles. The expression levels of MyBP-C slow were
signiﬁcantly increased in rat plantaris muscle induced to
hypertrophy by surgical ablation of the neighboring soleus
and gastrocnemius muscles, whereas the amounts of MyBP-
Cfastweredramaticallydecreased[72].Likewise,theprotein
levels of MyBP-C slow were increased in both chicken and
mouse dystrophic skeletal muscles [20, 24]. Further research
isrequiredinordertounderstandthemolecularmechanisms
that lead to the diﬀerential regulation of the skeletal forms
of MyBP-C in these models, and their potentially unique
roles in regulating the formation and activity of contractile
structures.
4.SummaryandFuturePerspectives
MyBP-C slow comprises a subfamily of at least four isoforms
that result from complex alternative splicing of the single
MyBP-C slow gene. The presence of the four MyBP-C slow
variants is not restricted to slow-twitch muscles, as select
isoforms are abundantly expressed in fast-twitch muscles,
too, where they may coexist with MyBP-C fast. More impor-
tantly,thefourisoformsofMyBP-Cslowmaybecoexpressed
in the same muscle, ﬁber or sarcomere, where they may
exhibit unique topographies concentrating either at A-bands
(variants 2, 3, and 4) or M-bands (variant 1). Previous and
current ﬁndings strongly favor a structural role for MyBP-
C slow at the sarcomeric A-a n dM-bands, and point to
a regulatory role on muscle contraction. Consequently, the
detailed characterization of the biochemical and biophysical
properties of the four MyBP-C slow variants, and the
development of the appropriate molecular tools and animal
models are imperative in order to study the cell biology and
functional properties of this intricate subfamily of proteins.
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